

Atherosclerosis 125 (1996) 275-277

Author index

Volume 125 (1996)

Akishita, M., Y. Ouchi, H. Miyoshi, A. Orimo, K. Kozaki, M. Eto, M. Ishikawa, S. Kim, K. Toba, H. Orimo, Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta 125, 27

Alexandersen, P., J. Haarbo, C. Christiansen, The relationship of natural androgens to coronary heart disease in males: a review 125, 1

Allison, B.A., J. Hamilton, Benzoporphyrin derivative decreases the binding of low density lipoprotein to the glycosaminoglycan chondroitin-6-sulfate in vitro 125, 153

Arii, K., see Nakauchi, Y. 125, 161 Ascaso, J.F., see Carmena, R. 125, 243

Bader, G., see Kraft, H.G. 125, 53
Baker, P.B., see Friedman, M.H. 125, 183
Banai, S., see Golomb, G. 125, 171
Bausserman, L., see Bostom, A.G. 125, 91
Bergstöm, M., see Carmena, R. 125, 243
Bertrand, P., see Chajara, A. 125, 193
Blom, H.J., see Franken, D.G. 125, 71

Boers, G.H.J., see Franken, D.G. 125, 71
Bostom, A.G., D. Shemin, K.L. Lapane, P.

Bostom, A.G., D. Shemin, K.L. Lapane, P. Sutherland, M.R. Nadeau, P.W.F. Wilson, D. Yoburn, L. Bausserman, G. Tofler, P.F. Jacques, J. Selhub, I.H. Rosenberg, Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched casecontrol study 125, 91

Brack, M., see Samani, N.J. 125, 209

Caldú, P., see Hurtado, I. 125, 39 Camejo, G., see Carmena, R. 125, 243 Cameron, J.D., see Dart, A.M. 125, 145 Carmena, R., J.F. Ascaso, G. Camejo, G

Carmena, R., J.F. Ascaso, G. Camejo, G. Varela, E. Hurt-Camejo, J.M. Ordovas, J. Martinez-Valls, M. Bergstöm, B.
 Wallin, Effect of olive and sunflower oils on low density lipoprotein level, composition, size, oxidation and interaction with arterial proteoglycans 125, 243

Chajara, A., H. Levesque, M.-N. Courel, C. Chauzy, C.

Maingonnat, P. Bertrand, B. Delpech, Hyaluronan and hyaluronectin production in injured rat thoracic aorta 125, 193

Chauhan, A., see Samani, N.J. 125, 209 Chauzy, C., see Chajara, A. 125, 193 Christiansen, C., see Alexandersen, P. 125, 1

Courel, M.-N., see Chajara, A. 125, 193

Cramb, R., see Rajman, I. 125, 231 Cruysberg, J.R.M., see Franken, D.G. 125, 71 Cullen, J., see Samani, N.J. 125, 209

Cuniberti, L.A., see Werba, J.P. 125, 257

Dart, A.M., X.L. Qi, J.D. Cameron, In vivo determinants of arterial stiffness 125, 145

Day, I.N.M., see Talmud, P.J. 125, 135 de Bono, D.P., see Samani, N.J. 125, 209 Delpech, B., see Chajara, A. 125, 193 Ding, Z., see Friedman, M.H. 125, 183

Elinder, L.S., see Regnström, J. 125, 217 Elisaf, M.C., see Karabina, S.-A.P. 125, 121 Eto, M., see Akishita, M. 125, 27

Fellermann, K., see Reimann, F.M. 125, 63 Fiol, C., see Hurtado, I. 125, 39 Fishbein, I., see Golomb, G. 125, 171

Foo, J.I., see Mamotte, C.D.S. 125, 103

Franken, D.G., G.H.J. Boers, H.J. Blom, J.R.M. Cruysberg, F.J.M. Trijbels, B.C.J. Hamel, Prevalence of familial mild hyperhomocysteinemia 125, 71

Friedman, M.H., P.B. Baker, Z. Ding, B.D. Kuban, Relationship between the geometry and quantitative morphology of the left anterior descending coronary artery 125, 183

Gammage, M.D., see Rajman, I. 125, 231

Garg, U., see Tsai, M.Y. 125, 267
Gaw, A., Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol? 125, 267

Gaffney, D., see Talmud, P.J. 125, 135
Gershlick, A.H., see Samani, N.J. 125, 209
Gertz, S.D., see Golomb, G. 125, 171
Golomb, G., I. Fishbein, S. Banai, D. Mishaly, D. Moscovitz,
S.D. Gertz, A. Gazit, E. Poradosu, A. Levitzki, Controlled delivery of a tyropostin inhibits intimal hyperplasia in a rat

Gazit, A., see Golomb, G. 125, 171

Gracia, V., see Hurtado, I. 125, 39

S.D. Gertz, A. Gazit, E. Poradosu, A. Levitzki, Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model 125, 171
Gosling, R.G., see Lehmann, E.D. 125, 139
Goudevenos, J., see Karabina, S.-A.P. 125, 121

Haarbo, J., see Alexandersen, P. 125, 1 Hamashige, N., see Nakauchi, Y. 125, 161 Hamel, B.C.J., see Franken, D.G. 125, 71 Hamilton, J., see Allison, B.A. 125, 153 Hanson, N.Q., see Tsai, M.Y. 125, 267 Harley, A., see Samani, N.J. 125, 209 Hashimoto, K., see Nakauchi, Y. 125, 161 Hatzistamou, J., see Kiaris, H. 125, 47 Heath, K., see Talmud, P.J. 125, 135 Higashi, T., see Sato, Y. 125, 15 Holder, R.L., see Rajman, I. 125, 231 Holme, I., see Regnström, J. 125, 217 Hopkins, K.D., see Lehmann, E.D. 125, 139 Horiuchi, S., see Sato, Y. 125, 15 Humphries, S.E., see Talmud, P.J. 125, 135 Hurt-Camejo, E., see Carmena, R. 125, 243 Hurtado, I., C. Fiol, V. Gracia, P. Caldú, In vitro oxidised HDL exerts a cytotoxic effect on macrophages 125, 39

Ishikawa, M., see Akishita, M. 125, 27

Jacques, P.F., see Bostom, A.G. 125, 91 Johansson, J., see Regnström, J. 125, 217

Karabina, S.-A.P., M.C. Elisaf, J. Goudevenos, K.C. Siamo-poulos, D. Sideris, A.D. Tselepis, PAF-acetylhydrolase activity on Lp(a) before and during Cu²⁺-induced oxidative modification in vitro 125, 121

Kendall, M.J., see Rajman, I. 125, 231 Key, N.S., see Tsai, M.Y. 125, 267

Kiaris, H., J. Hatzistamou, D.A. Spandidos, Instability at the H-ras minisatellite in human atherosclerotic plaques 125, 47

Kim, S., see Akishita, M. 125, 27 Kobori, S., see Sato, Y. 125, 15

Kostner, G.M., see Kraft, H.G. 125, 53

Kotze, M.J., see Langenhoven, E. 125, 111

Kozaki, K., see Akishita, M. 125, 27

Kraft, H.G., A. Lingenhel, G. Bader, G.M. Kostner, G. Utermann, The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes 125, 53

Kuban, B.D., see Friedman, M.H. 125, 183 Kumon, Y., see Nakauchi, Y. 125, 161

Laguens, R.P., see Werba, J.P. 125, 257

Langenhoven, E., L. Warnich, R. Thiart, D.C. Rubinsztein, D.R.v.d. Westhuyzen, A.D. Marais, M.J. Kotze, Two novel point mutations causing receptor-negative familial hypercholesterolemia in a South African Indian homozygote 125, 111

Lapane, K.L., see Bostom, A.G. 125, 91

Lehmann, E.D., K.D. Hopkins, R.G. Gosling, In vivo determinants of arterial stiffness 125, 139

Lei, X., L. Maximilian Buja, Detection and localization of tumor necrosis factor-α in WHHL rabbit arteries 125, 81

Levesque, H., see Chajara, A. 125, 193 Levitzki, A., see Golomb, G. 125, 171 Levy, R., see Werba, J.P. 125, 257 Lingenhel, A., see Kraft, H.G. 125, 53

Lodwick, D., see Samani, N.J. 125, 209

Maingonnat, C., see Chajara, A. 125, 193
 Mamotte, C.D.S., M. Sturm, J.I. Foo, F.M. van Bockxmeer,
 R.R. Taylor, Familial defective apolipoprotein B-100
 (FDB): effect of simvastatin therapy on LDL-receptor binding 125, 103

binding 125, 103
Marais, A.D., see Langenhoven, E. 125, 111
Martin, D.S., see Samani, N.J. 125, 209
Martinez-Valls, J., see Carmena, R. 125, 243
Masnatta, L.D., see Werba, J.P. 125, 257
Matsumura, T., see Sato, Y. 125, 15
Maximilian Buja, L., see Lei, X. 125, 81
Mishaly, D., see Golomb, G. 125, 171
Miyazaki, A., see Sato, Y. 125, 15

Miyoshi, H., see Akishita, M. 125, 27 Morikawa, W., see Sato, Y. 125, 15 Moscovitz, D., see Golomb, G. 125, 171

Mölgaard, J., see Regnström, J. 125, 217

Nadeau, M.R., see Bostom, A.G. 125, 91

Nakauchi, Y., T. Suehiro, M. Yamamoto, N. Yasuoka, K. Arii, Y. Kumon, N. Hamashige, K. Hashimoto, Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease 125, 161

Nilsson, J., see Regnström, J. 125, 217

Nilsson, S., see Regnström, J. 125, 217
Olsson, A.G., see Regnström, J. 125, 217

Ordovas, J.M., see Carmena, R. 125, 243 Orimo, A., see Akishita, M. 125, 27 Orimo, H., see Akishita, M. 125, 27 Ouchi, Y., see Akishita, M. 125, 27

Pichel, R.H., see Werba, J.P. **125**, 257 Poradosu, E., see Golomb, G. **125**, 171

Qi, X.L., see Dart, A.M. 125, 145

Rajman, I., M.J. Kendall, R. Cramb, R.L. Holder, M. Salih, M.D. Gammage, Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men 125, 231 Regnström, J., G. Walldius, S. Nilsson, L.S. Elinder, J. Johansson, J. Mölgaard, I. Holme, A.G. Olsson, J. Nilsson, The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis 125, 217

Reimann, F.M., F. Winkelmann, K. Fellermann, E.F. Stange, Reduced cholesterol esterification in CaCo-2 cells by indi-

rect action of pravastatin 125, 63 Rey, R.H., see Werba, J.P. 125, 257 Rosenberg, I.H., see Bostom, A.G. 125, 91 Rubinsztein, D.C., see Langenhoven, E. 125, 111

Sakai, M., see Sato, Y. 125, 15 Salih, M., see Rajman, I. 125, 231

Samani, N.J., D.S. Martin, M. Brack, J. Cullen, R. Wallis, D. Lodwick, A. Chauhan, A. Harley, J.R. Thompson, A.H. Gershlick, D.P. de Bono, Apolipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty 125, 209

Sato, Y., S. Kobori, M. Sakai, T. Yano, T. Higashi, T. Matsumura, W. Morikawa, T. Terano, A. Miyazaki, S. Horiuchi, M. Shichiri, Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor- β activation 125, 15

Schwichtenberg, K., see Tsai, M.Y. 125, 267 Selhub, J., see Bostom, A.G. 125, 91 Shemin, D., see Bostom, A.G. 125, 91 Shichiri, M., see Sato, Y. 125, 15 Siamopoulos, K.C., see Karabina, S.-A.P. 125, 121 Sideris, D., see Karabina, S.-A.P. 125, 121 Spandidos, D.A., see Kiaris, H. 125, 47 Stange, E.F., see Reimann, F.M. 125, 63

Sturm, M., see Mamotte, C.D.S. 125, 103 Suehiro, T., see Nakauchi, Y. 125, 161

Suh, A., see Tsai, M.Y. 125, 267

Sutherland, P., see Bostom, A.G. 125, 91

Talmud, P.J., O.J. Tamplin, K. Heath, D. Gaffney, I.N.M. Day, S.E. Humphries, Rapid testing for three mutations causing familial defective apolipoprotein B100 in 562 patients with familial hypercholesterolaemia 125, 135

Tamplin, O.J., see Talmud, P.J. 125, 135

Taylor, R.R., see Mamotte, C.D.S. 125, 103

Terano, T., see Sato, Y. 125, 15

Thiart, R., see Langenhoven, E. 125, 111

Thompson, J.R., see Samani, N.J. 125, 209

Toba, K., see Akishita, M. 125, 27

Tofler, G., see Bostom, A.G. 125, 91 Trijbels, F.J.M., see Franken, D.G. 125, 71

Tsai, M.Y., U. Garg, N.S. Key, N.Q. Hanson, A. Suh, K. Schwichtenberg, Erratum to "Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria" [Atherosclerosis 122 (1996) 69]¹ 125,

Tselepis, A.D., see Karabina, S.-A.P. 125, 121

Utermann, G., see Kraft, H.G. 125, 53

van Bockxmeer, F.M., see Mamotte, C.D.S. 125, 103 Varela, G., see Carmena, R. 125, 243

Walldius, G., see Regnström, J. 125, 217 Wallin, B., see Carmena, R. 125, 243 Wallis, R., see Samani, N.J. 125, 209

Warnich, L., see Langenhoven, E. 125, 111

Werba, J.P., L.A. Cuniberti, R.P. Laguens, L.D. Masnatta, R.H. Rey, R. Levy, R.H. Pichel, Injury produces early rise in lipoprotein lipase activity in rabbit aorta 125, 257

Westhuyzen, D.R.v.d., see Langenhoven, E. 125, 111 Wilson, P.W.F., see Bostom, A.G. 125, 91

Winkelmann, F., see Reimann, F.M. 125, 63

Yamamoto, M., see Nakauchi, Y. 125, 161

Yano, T., see Sato, Y. 125, 15 Yasuoka, N., see Nakauchi, Y. 125, 161 Yoburn, D., see Bostom, A.G. 125, 91





Atherosclerosis 125 (1996) 279-280

Subject index

Volume 125 (1996)

Acyl-CoA cholesteryl acyltransferase 125, 63 Androgens 125, 1 Angiography 125, 183 Angiotensin-converting enzyme 125, 209 Angiotensin I-converting enzyme 125, 161 Angiotensin II type 1 receptor 125, 161 Animal model 125, 257 Aorta 125, 193 Apo(a) 125, 53 Apo(a) isoform 125, 121 apoB Mutation testing 125, 135 Apolipoprotein(a) 125, 15 Apolipoprotein E 125, 209 Arterial distensibility 125, 139 Arteriosclerosis 125, 91 Atherosclerosis 125, 27, 39, 47, 257

Benzoporphyrin derivative 125, 153

Atherosis 125, 139

CaCo-2 cell 125, 63 c-fos 125, 27 Cholesterol 125, 63 Cholestyramine 125, 217 Chondroitin-6-sulfate 125, 153 Compliance 125, 139 Controlled release 125, 171 Coronary angiography 125, 161 Coronary artery 125, 183 Coronary artery disease 125, 231 Coronary heart disease 125, 231 Cytotoxicity 125, 39

Diets 125, 243 DNA diagnosis 125, 111 Drug implants 125, 171

Endothelin 125, 27 End-stage renal disease 125, 91 Estrogen 125, 27 Familial 125, 71
Familial defective apoB100 125, 135
Familial defective apolipoprotein B-100 125, 103
Familial hypercholesterolaemia 125, 135
Fibrinogen 125, 91

Genes 125, 209 Genetic instability 125, 47

High density lipoprotein 125, 217
Histomorphology 125, 183
HMG-CoA reductase inhibitors 125, 63
HMGCoA reductase inhibitors 125, 103
Homocysteine 125, 91
H-ras 125, 47
Human atherosclerosis 125, 217
Hyaluronan 125, 193
Hyaluronectin 125, 193
Hyperhomocysteinemia 125, 71

Immunocytochemistry 125, 81 Implantable drug delivery system 125, 171 Initiation codon mutation 125, 111 Injury 125, 193 In situ transcription 125, 81 Intimal proliferation 125, 257

Lag phase 125, 39 LDL 125, 63 LDL affinity to proteoglycans 125, 243 LDL β carotene 125, 243 LDL oxidation 125, 243 LDL-receptor 125, 103 LDL retinol 125, 243 LDL size 125, 243 LDL subfractions 125, 231 LDL α-tocopherol 125, 243 Lipids 125, 139 Lipid-soluble vitamins 125, 217 Lipoprotein(a) 125, 15 Lipoprotein (a) 125, 121

- Lipoprotein lipase 125, 257 Low density lipoprotein 125, 153, 217 Low density lipoprotein receptor 125, 111 Lp(a) 125, 91 Lysophosphatidylcholine 125, 121
- Macrophage growth 125, 15 Macrophages 125, 39 Males 125, 1 Minisatellite 125, 47
- Olive oil 125, 243 Oxidation 125, 121, 217 Oxidised HDL 125, 39 Oxidised LDL 125, 39
- PAF-acetylhydrolase 125, 121 PFGE 125, 53 Phenotyping 125, 53 Photodynamic therapy 125, 153 Polymerase chain reaction 125, 111 Polymorphism 125, 53, 161 Pravastatin 125, 63 Probucol 125, 217 Protein tyrosine kinase 125, 171 PTCA 125, 209

- Pulse wave velocity 125, 139
- Quantitative arteriography 125, 217
- Rat 125, 193 Restenosis 125, 171, 209
- Sclerosis 125, 139 SDS electrophoresis 125, 53 Simvastatin 125, 103 Smooth muscle cell 125, 27 Stiffness 125, 139 Sunflower oil 125, 243 Susceptibility 125, 39
- Tetrazolium salts 125, 63 TGF-β 125, 15 TNF-α mRNA 125, 81 Triglycerides 125, 231 Tyrphostin 125, 171
- Vascular disease 125, 71 Vascular geometry 125, 183
- WHHL rabbit 125, 81

